Maroteaux-Lamy syndrome (mucopolysaccharidosis VI, MPS VI) is an inherited, progressive disease that leads to dysfunction in a range of organs and ultimately severe disability.¹ It is caused by a deficiency in the critical metabolic enzyme arylsulfatase B (ASB). This defective metabolic process leads to a wide range of symptoms in multiple organs. Enzyme replacement therapy (ERT) addresses that process by providing cells with the deficient enzyme ASB,² affecting multiple aspects of the disease.